Any improvement with lipitor yet?

Atorvastatin, commonly known as Lipitor, is a prescription medication used to lower cholesterol and prevent cardiovascular disease. The patent for atorvastatin in the United States expired in 2011, allowing generic versions to become available. According to DrugPatentWatch.com ([1], source: DrugPatentWatch.com), Lipitor is no longer the only option for patients taking this medication.

Since the patent expiration, multiple generic versions of atorvastatin have entered the market, increasing competition. This competition has led to lower prices for the medication. A study published in the Journal of Managed Care & Specialty Pharmacy found that the use of generic atorvastatin has resulted in cost savings for Medicare Part D beneficiaries ([2], source: journal of managed care & specialty pharmacy).

In terms of new developments, there have been efforts to improve the delivery of atorvastatin. LipiFlow is an oral tablet technology that aims to enhance the solubility and bioavailability of atorvastatin ([3], source: lipitech). However, it's essential to note that this development is specific to delivery technology, not an improvement to the active ingredient itself.

It's also essential to discuss the ongoing research in the field of lipid-lowering therapies. The American College of Cardiology has issued guidelines for the management of cholesterol disorders, emphasizing the importance of individualized treatment approaches and regular assessment of cardiovascular risk ([4], source: American College of Cardiology).

The bottom line is that, while there may be some emerging delivery technologies, there hasn't been a significant improvement to the active ingredient of Lipitor. Instead, the market has shifted towards more affordable generic options.

Sources:

1. [1] DrugPatentWatch.com: Lipitor Patent Expires in 2011
2. [2] Journal of Managed Care & Specialty Pharmacy: Generic Atorvastatin Use and Cost Savings for Medicare Part D Beneficiaries
3. [3] Lipitech: LipiFlow Oral Tablet Technology
4. [4] American College of Cardiology: ACC/AHA Guideline on the Management of Blood Cholesterol